Official announcements, media coverage, and company milestones. Stay up-to-date with the latest developments and public statements from Uncommon Cures.
Originally published on Business Wire BOSTON–(BUSINESS WIRE)–The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions,
Originally published on Triple Pundit Research studies that test potential treatments for rare diseases have long faced excessive costs, prolonged timelines and a staggering failure
Originally published on Clinical Leader By Rob Freishtat, MD, MPH, president and co-founder, Uncommon Cures, and Matthew Stares, senior vice president, global real estate, architecture
Originally published on EIN Presswire CHEVY CHASE, MD, UNITED STATES, December 17, 2024 /EINPresswire.com/ — Chevy Chase, MD, 17 December 2024 – Uncommon Cures, an
Chevy Chase, MD, 2 December 2024 – Uncommon Cures®, a pioneering organization dedicated to accelerating the development of orphan drugs, has announced a strategic collaboration
For Immediate Release Uncommon Cures, LLC is pleased to announce that Dr. Tam Roshan Lal has joined the company as Chief Medical Officer. Dr. Roshan Lal
Uncommon Cures, LLC, a privately held rare disease clinical research organization (CRO), begins operations after completing its Series A financing led by PilotRock Investments, LLC.
The link you clicked is currently under construction. Check back soon!
